Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Granzyme B mediates degradation of dermal-epidermal junction proteins in Stevens-Johnson syndrome and toxic epidermal necrolysis
EF 2022-23
Résumé
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious diseases that involve peeling and blistering of the skin. SJS is on the less serious side while TEN has worse outcomes. While these diseases are rare, those afflicted by them have a mortality rate between 10-34%. Granzyme B (GzmB) is a protein, known as a protease, that can cut other proteins. This can have consequences when there are high levels of GzmB in the space surrounding skin cells known as the extracellular matrix (ECM). GzmB is mostly known for its involvement in killing other cells by a mechanism called apoptosis; however, it has recently been shown to be active in the ECM. Importantly, GzmB is known to specifically cut proteins that are important for connecting the two layers of skin, the dermal epidermal junction (DEJ), and degradation of these proteins can lead to blistering. As GzmB has been shown to be found at high levels in SJS and TEN patient blister fluid, we believe that GzmB is responsible for cutting these proteins between the two skin layers,leading to the separation of the DEJ. To test if GzmB plays a key role, we will carry out several experiments. Firstly, we will look to see if there is a loss of DEJ proteins in SJS and TEN patient skin samples. Secondly, we will look at SJS and TEN patient blister fluid for high levels of GzmB and fragments of DEJ proteins. Finally, we will place blister fluid with skin cells with and without a molecule that blocks GzmB action to see if GzmB is responsible for the breakdown of DEJ proteins. As both SJS and TEN are life-threatening, it is very important to better understand proteins like GzmB to see if there is a way to develop drugs that can prevent its actions and to increase odds of survival.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486290
Name
Lane Michael M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Granzyme B mediates degradation of dermal-epidermal junction proteins in Stevens-Johnson syndrome and toxic epidermal necrolysis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune; Blistering; Cutaneous; Dermal-Epidermal Junction; Drug Reaction; Epidermal Necrolysis; Granzyme B; Stevens-Johnson Syndrome; Toxic Epidermal Necrolysis; Wound Healing
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious diseases that involve peeling and blistering of the skin. SJS is on the less serious side while TEN has worse outcomes. While these diseases are rare, those afflicted by them have a mortality rate between 10-34%. Granzyme B (GzmB) is a protein, known as a protease, that can cut other proteins. This can have consequences when there are high levels of GzmB in the space surrounding skin cells known as the extracellular matrix (ECM). GzmB is mostly known for its involvement in killing other cells by a mechanism called apoptosis; however, it has recently been shown to be active in the ECM. Importantly, GzmB is known to specifically cut proteins that are important for connecting the two layers of skin, the dermal epidermal junction (DEJ), and degradation of these proteins can lead to blistering. As GzmB has been shown to be found at high levels in SJS and TEN patient blister fluid, we believe that GzmB is responsible for cutting these proteins between the two skin layers,leading to the separation of the DEJ. To test if GzmB plays a key role, we will carry out several experiments. Firstly, we will look to see if there is a loss of DEJ proteins in SJS and TEN patient skin samples. Secondly, we will look at SJS and TEN patient blister fluid for high levels of GzmB and fragments of DEJ proteins. Finally, we will place blister fluid with skin cells with and without a molecule that blocks GzmB action to see if GzmB is responsible for the breakdown of DEJ proteins. As both SJS and TEN are life-threatening, it is very important to better understand proteins like GzmB to see if there is a way to develop drugs that can prevent its actions and to increase odds of survival.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lane, Michael M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~